Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rang in aandelen #29898
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Aandeelprijs
$1.10
Laatst gesynchroniseerd: 2023-06-07
Marktkapitalisatie
$19.12M
Verandering (1 dag)
-0.90%
Verandering (1 jaar)
0.00%
Land
US
Handel Satsuma Pharmaceuticals, Inc. (STSA)

Categorie

Dividendrendementgeschiedenis voor Satsuma Pharmaceuticals, Inc. (STSA)
Het dividendrendement (TTM) van Satsuma Pharmaceuticals, Inc. (aandelsymbool: STSA) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Satsuma Pharmaceuticals, Inc. (STSA) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten